Metropolitan Life Insurance Company (MetLife)’s BioXcel Therapeutics BTAI Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-63	Closed	-$6.76K	–	2406
2023 Q2	$6.76K	Hold	63	–	–	﹤0.01%	2434
2023 Q1	$18.9K	Sell	63 -19	-23%	-$8.11K	﹤0.01%	1910
2022 Q4	$28K	Hold	82	–	–	﹤0.01%	1823
2022 Q3	$15.4K	Hold	82	–	–	﹤0.01%	2143
2022 Q2	$17.2K	Hold	82	–	–	﹤0.01%	2111
2022 Q1	$27.3K	Sell	82 -223	-73%	-$64.6K	﹤0.01%	1936
2021 Q4	$99.3K	Hold	305	–	–	﹤0.01%	2488
2021 Q3	$148K	Buy	305 +57	+23%	+$25.1K	﹤0.01%	2297
2021 Q2	$115K	Buy	248 +35	+16%	+$19.1K	﹤0.01%	2520
2021 Q1	$147K	Hold	213	–	–	﹤0.01%	2223
2020 Q4	$157K	Hold	213	–	–	﹤0.01%	2104
2020 Q3	$147K	Hold	213	–	–	﹤0.01%	1974
2020 Q2	$180K	Buy	213 +178	+509%	+$116K	﹤0.01%	1870
2020 Q1	$12.4K	Buy	+35	New	+$12.6K	﹤0.01%	2480

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BTAI Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 63 shares — an estimated $6.76K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BTAI in Q1 2020 and held it in 14 quarters. The position peaked at $180K in Q2 2020. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 63 BioXcel Therapeutics shares in Q3 2023, an estimated $6.76K.
Metropolitan Life Insurance Company (MetLife) first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 14 quarters.
Metropolitan Life Insurance Company (MetLife)'s BioXcel Therapeutics position peaked at $180K in Q2 2020.
85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.